Study of Probucol Added to Statin Therapy to Reduce Vascular Risks and Atherosclerosis in Adults with Ischemic Stroke

What this Trial Is About

Researchers are evaluating whether combining Probucol with statin therapy can better reduce vascular event risks and improve atherosclerosis outcomes in adults who have had an ischemic stroke and confirmed atherosclerosis. This prospective, open-label study investigates if adding Probucol to guideline-recommended statin therapy decreases plaque burden and lowers the chance of cardiovascular and cerebrovascular events compared to statins alone. Participants will either receive standard lipid-lowering therapy based on current guidelines, which may include statins, ezetimibe, or PCSK9 inhibitors, or the same therapy combined with Probucol 0.5 grams twice daily. The study will include at least 100 participants in each group and follow them over a period of three years to monitor effects on atherosclerosis progression and vascular outcomes. During the study, participants will attend regular follow-up visits to assess changes in plaque burden and atherosclerotic features through imaging studies and blood tests. Researchers will measure lipid levels and biomarkers such as LDL-C, Ox-LDL, and Lpa, while monitoring for cardiovascular events and safety outcomes. The primary measurement is the change in plaque burden from baseline to 12 months, with additional assessments at 1, 12, and 24 months to evaluate functional outcomes and vascular event occurrence.

Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke